Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma
暂无分享,去创建一个
Jinyao Zhao | XINCHEN ZHANG | GORDON GUO | GUANG WANG | JINYAO ZHAO | BO WANG | XIAOTANG YU | YANFANG DING | Xiaotang Yu | Bo Wang | G. Guo | Yanfang Ding | Guang Wang | Xinchen Zhang
[1] Dan Han,et al. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma , 2013, Tumor Biology.
[2] Elizabeth Swisher,et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features , 2012, World Journal of Surgical Oncology.
[3] X. Qin,et al. miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. , 2012, Experimental and therapeutic medicine.
[4] N. Matsumura,et al. Recent Concepts of Ovarian Carcinogenesis: Type I and Type II , 2014, BioMed research international.
[5] Yanchun Ding,et al. Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research. , 2012, Methods.
[6] Chang-Zheng Chen,et al. MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.
[7] Hong-Fei Wu,et al. A Ten-MicroRNA Signature Identified from a Genome-Wide MicroRNA Expression Profiling in Human Epithelial Ovarian Cancer , 2014, PloS one.
[8] Tadashi Kimura,et al. The Role of MicroRNAs in Ovarian Cancer , 2014, BioMed research international.
[9] Shivani R. Kandukuri,et al. FIGO 2013 staging system for ovarian cancer: what is new in comparison to the 1988 staging system? , 2015, Current opinion in obstetrics & gynecology.
[10] Ben Davidson,et al. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker , 2014, BMC Cancer.
[11] A. Jemal,et al. Global Cancer Statistics , 2011 .
[12] L. De Cecco,et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients , 2011, Oncotarget.
[13] R. Kurman. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] David P Turner,et al. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer , 2012, Breast Cancer Research.
[15] R. Zeineldin,et al. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. , 2011, Gynecologic oncology.
[16] Wei Zhu,et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth , 2012, Oncogene.
[17] S. Knudsen,et al. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. , 2010, Cancer research.
[18] A. Jemal,et al. Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[19] S. Rosenwald,et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.
[20] A. Scorilas,et al. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. , 2013, Clinical chemistry.
[21] Andrea Ventura,et al. MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.
[22] D. Aoki,et al. Application of MicroRNA in Diagnosis and Treatment of Ovarian Cancer , 2014, BioMed research international.
[23] Artemis G. Hatzigeorgiou,et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.
[24] E. Oliva,et al. Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases , 2015, Histopathology.
[25] C. Gilks,et al. Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.
[26] Brock A. Humphries,et al. MicroRNAs: Novel Players in Cancer Diagnosis and Therapies , 2014, BioMed research international.
[27] P. Sadłecki,et al. Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer , 2013, International journal of endocrinology.
[28] E. Berns,et al. MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.
[29] A. Godwin,et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management , 2009, Molecular oncology.
[30] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[31] Sheila M. Reynolds,et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. , 2013, Cancer cell.
[32] Anil K Sood,et al. Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.